Summary
1.84 0.06(3.08%)10/04/2024
Compugen Ltd (CGEN)
Compugen Ltd (CGEN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.38 | 1.66 | -7.32 | 18.39 | -21.24 | 118.45 | -57.23 | -83.51 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.84 | |
| Open | 1.82 | |
| High | 1.84 | |
| Low | 1.78 | |
| Volume | 87,500 | |
| Change | 0.06 | |
| Change % | 3.38 | |
| Avg Volume (20 Days) | 192,049 | |
| Volume/Avg Volume (20 Days) Ratio | 0.46 | |
| 52 Week Range | 0.53 - 3.03 | |
| Price vs 52 Week High | -39.44% | |
| Price vs 52 Week Low | 246.23% | |
| Range | 0.82 | |
| Gap Up/Down | -0.16 | |
Fundamentals | ||
| Market Capitalization (Mln) | 157 | |
| EBIDTA | -12,516,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 5.33 | |
| Book Value | 0.7350 | |
| Earnings Per Share | -0.2100 | |
| EPS Estimate Current Quarter | 0.2200 | |
| EPS Estimate Next Quarter | 0.0700 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | -0.2900 | |
| Diluted EPS (TTM) | -0.2100 | |
| Revenues | ||
| Profit Marging | -0.5605 | |
| Operating Marging (TTM) | 0.5375 | |
| Return on asset (TTM) | -0.0754 | |
| Return on equity (TTM) | -0.2619 | |
| Revenue TTM | 33,459,000 | |
| Revenue per share TTM | 0.3820 | |
| Quarterly Revenue Growth (YOY) | 3.4610 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 6,525,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.9088 | |
| Revenue Enterprise Value | 4.5383 | |
| EBITDA Enterprise Value | -12.1322 | |
| Shares | ||
| Shares Outstanding | 89,530,200 | |
| Shares Float | 84,693,772 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 5.38 | |
| Institutions (%) | 14.72 | |
09/11 13:00 EST - zacks.com
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
09/09 07:00 EST - prnewswire.com
Compugen to Present at Single Cell Genomics 2024 Conference
HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd.
Compugen to Present at Single Cell Genomics 2024 Conference
HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd.
08/29 07:00 EST - prnewswire.com
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C.
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C.
08/26 13:20 EST - zacks.com
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
08/10 05:54 EST - seekingalpha.com
Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.
Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.
08/06 09:26 EST - zacks.com
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago.
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago.
08/06 07:00 EST - prnewswire.com
Compugen Reports Second Quarter 2024 Results
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024 Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the Company Solid balance sheet with cash runway expected to fund operations into 2027 HOLON, Israel , Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd.
Compugen Reports Second Quarter 2024 Results
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024 Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the Company Solid balance sheet with cash runway expected to fund operations into 2027 HOLON, Israel , Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd.
07/29 07:00 EST - prnewswire.com
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer therapeutics as monotherapy and in combination in advanced solid tumors in Q4 2024 HOLON, Israel , July 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead Sciences, Inc. (Gilead).
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer therapeutics as monotherapy and in combination in advanced solid tumors in Q4 2024 HOLON, Israel , July 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead Sciences, Inc. (Gilead).
07/23 07:00 EST - prnewswire.com
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets open.
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets open.
06/17 07:00 EST - prnewswire.com
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France.
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France.
06/04 10:56 EST - zacks.com
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
05/30 07:00 EST - prnewswire.com
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening the assessment of rilvegostomig reinforces Compugen's partnering strategy to expand opportunities for its pipeline Compugen to receive $5 million milestone payment from AstraZeneca HOLON, Israel , May 30, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody.
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening the assessment of rilvegostomig reinforces Compugen's partnering strategy to expand opportunities for its pipeline Compugen to receive $5 million milestone payment from AstraZeneca HOLON, Israel , May 30, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody.
05/20 12:22 EST - seekingalpha.com
Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q1 2024 Earnings Call Transcript May 20, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of IR & Corporate Communications Anat Cohen-Dayag - President and CEO Alberto Sessa - CFO Eran Ophir - CSO Michelle Mahler - CMO Conference Call Participants Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.
Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q1 2024 Earnings Call Transcript May 20, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of IR & Corporate Communications Anat Cohen-Dayag - President and CEO Alberto Sessa - CFO Eran Ophir - CSO Michelle Mahler - CMO Conference Call Participants Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.
05/20 07:00 EST - prnewswire.com
Compugen Reports First Quarter 2024 Results
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 + COM902 + pembrolizumab study in microsatellite stable colorectal cancer with liver metastases planned to be presented at ASCO 2024 annual meeting On track to submit IND for COM503 in the second half of 2024 with preparation for Phase 1 study well advanced Partner, AstraZeneca, progressed rilvegostomig into second Phase 3 trial in nonsquamous NSCLC; Compugen eligible for development milestone payments for this second indication Solid balance sheet with extended cash runway expected to fund operations into 2027 HOLON, Israel , May 20, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
Compugen Reports First Quarter 2024 Results
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 + COM902 + pembrolizumab study in microsatellite stable colorectal cancer with liver metastases planned to be presented at ASCO 2024 annual meeting On track to submit IND for COM503 in the second half of 2024 with preparation for Phase 1 study well advanced Partner, AstraZeneca, progressed rilvegostomig into second Phase 3 trial in nonsquamous NSCLC; Compugen eligible for development milestone payments for this second indication Solid balance sheet with extended cash runway expected to fund operations into 2027 HOLON, Israel , May 20, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
05/16 07:00 EST - prnewswire.com
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
HOLON, Israel, May 16, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the online publication of a peer reviewed paper titled "PVRIG is expressed on stem-like T cells in dendritic cell-rich niches in tumors and its blockade may induce immune infiltration in non-inflamed tumors" link, in Cancer Immunology Research, a journal of the American Association for Cancer Research.
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
HOLON, Israel, May 16, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the online publication of a peer reviewed paper titled "PVRIG is expressed on stem-like T cells in dendritic cell-rich niches in tumors and its blockade may induce immune infiltration in non-inflamed tumors" link, in Cancer Immunology Research, a journal of the American Association for Cancer Research.
05/15 07:00 EST - prnewswire.com
Compugen Appoints David Silberman as Chief Financial Officer
HOLON, Israel , May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day.
Compugen Appoints David Silberman as Chief Financial Officer
HOLON, Israel , May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day.
05/06 07:00 EST - prnewswire.com
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open.
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open.
04/25 07:00 EST - prnewswire.com
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.
04/10 07:00 EST - prnewswire.com
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.
04/03 07:00 EST - prnewswire.com
Compugen to Participate in Two Upcoming Investor Conferences
HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming investor conferences in April: 23rd Annual Needham Virtual Healthcare Conference Date: Wednesday, April 10, 2024, at 8:00 AM ET Location: Virtual Format: Presentation Canaccord Genuity Horizons in Oncology Virtual Conference Date: Monday, April 15, 2024, at 9:00 AM ET Location: Virtual Format: Panel: Novel Immune Checkpoints - There's more than one way to stimulate a T-cell Live webcast of the presentation and a replay will be available on the Investor Relations section of Compugen's website at www.cgen.com.
Compugen to Participate in Two Upcoming Investor Conferences
HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming investor conferences in April: 23rd Annual Needham Virtual Healthcare Conference Date: Wednesday, April 10, 2024, at 8:00 AM ET Location: Virtual Format: Presentation Canaccord Genuity Horizons in Oncology Virtual Conference Date: Monday, April 15, 2024, at 9:00 AM ET Location: Virtual Format: Panel: Novel Immune Checkpoints - There's more than one way to stimulate a T-cell Live webcast of the presentation and a replay will be available on the Investor Relations section of Compugen's website at www.cgen.com.